Download MendeleyImproved Binding Affinity and Pharmacokinetics Enable Sustained Degradation of BCL6 In Vivo .
Huckvale, R., Harnden, A.C., Cheung, K.J., Pierrat, O.A., Talbot, R., Box, G.M., Henley, A.T., de Haven Brandon, A.K., Hallsworth, A.E., Bright, M.D., Akpinar, H.A., Miller, D.S.J., Tarantino, D., Gowan, S., Hayes, A., Gunnell, E.A., Brennan, A., Davis, O.A., Johnson, L.D., de Klerk, S., McAndrew, C., Le Bihan, Y.V., Meniconi, M., Burke, R., Kirkin, V., van Montfort, R.L.M., Raynaud, F.I., Rossanese, O.W., Bellenie, B.R., Hoelder, S.(2022) J Med Chem 65: 8191-8207
- PubMed: 35653645
- DOI: https://doi.org/10.1021/acs.jmedchem.1c02175
- Primary Citation of Related Structures:
7QK0 - PubMed Abstract:
The transcriptional repressor BCL6 is an oncogenic driver found to be deregulated in lymphoid malignancies. Herein, we report the optimization of our previously reported benzimidazolone molecular glue-type degrader CCT369260 to CCT373566 , a highly potent probe suitable for sustained depletion of BCL6 in vivo . We observed a sharp degradation SAR, where subtle structural changes conveyed the ability to induce degradation of BCL6. CCT373566 showed modest in vivo efficacy in a lymphoma xenograft mouse model following oral dosing.
Organizational Affiliation:
Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SM2 5NG, U.K.
